Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2022/23 Earnings Presentation
101 slides from Coloplast A/s Class B's earnings presentation, May 2023
Slide 1: Roadshow presentation H1 2022/23
Roadshow presentation H1 2022/23 Kjell, Denmark Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid 8% organic growth and 28% EBIT margin in Q2; guidance narrowed
Solid 8% organic growth and 28% EBIT margin1 in Q2. FY 2022/23 guidance narrowed: ~8% organic growth and 28-29% EBIT margin1 REVENUE GROWTH Q2 2022/23 highlights • Organic growth of 8% and reported growth in DKK of 10% Reported revenue (mDKK) Organic growth • Continued good momentum in Chronic Care
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation US Chronic Care Chronic Care – Clinical Performance Programme • Strong performance in the US Ostomy Care business, where Coloplast continues to • Luja™, the new male intermittent catheter with a Micro-hole Zone Tech
Slide 5: Solid 8% organic growth in Q2 across business areas and regions
Solid 8% organic growth in Q2 with broad-based contribution from all business areas and regions excluding China Q2 2022/23 revenue by business area Q2 2022/23 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth Share of orga
Slide 6: Ostomy Care grew 6% in Q2
Ostomy Care grew 6% in Q2 with solid contribution from all regions ex. China. China detracted from growth due to COVID-19, as expected Ostomy Care performance Q2 2022/23 highlights • All regions contributed to growth ex. China • Solid growth contribution from Europe, driven by the UK and Germany 13
Slide 7: Continence Care grew 6% in Q2
Continence Care grew 6% in Q2 with contribution from all segments and regions Continence Care performance Q2 2022/23 highlights • Solid contribution to growth from all regions • Sales growth in Europe was driven by the UK and Germany 11 9 9 • Continued good sales momentum in the US 8 6 • Emerging ma
Slide 8: Voice & Respiratory Care delivered 9% organic growth in Q2
Voice & Respiratory Care delivered 9% organic growth in Q2 with solid momentum in both Laryngectomy and Tracheostomy Voice & Respiratory Care performance Q2 2022/23 highlights • February 1, 2023, marked the one-year anniversary of the completion of the Atos Medical acquisition. The business has cont
Slide 9: Strong Q2 in Wound & Skin Care with 13% growth
Strong Q2 in Wound & Skin Care with 13% growth driven by solid momentum in Wound Care Europe, including benefit from a low baseline Wound & Skin Care performance Q2 2022/23 highlights • Wound Care in isolation grew 12% despite continued negative impact from 14 backorders, as expected 9 10 13 5 5 • T
Slide 10: Strong momentum in Interventional Urology with 17% growth
Strong momentum in Interventional Urology with broad-based growth of 17%, led by the US Men’s Health business Interventional Urology performance Q2 2022/23 highlights • Growth in the quarter was driven by continued strong momentum across business areas and geographies, as well as positive impact fro
Slide 11: Q2 reported growth up 10%, Atos and currency effects
Q2 reported growth was up 10%, with ~3%-points impact from the Atos Medical acquisition and ~1%-point negative currency effect Q2 2022/23 Revenue development (DKKm) Q2 2022/23 highlights • Organic growth was 8% or DKK 453 million, driven by: 558m DKK • Continued solid momentum in Chronic Care across
Slide 12: Reported EBIT margin of 28% in Q2
Reported EBIT margin of 28%1 in Q2, reflecting inflationary headwind on input costs, increased level of commercial activity, and amortisation costs Q2 2022/23 EBIT margin development before special items (%) Q2 2022/23 highlights • Gross margin was 66%, against 69% in Q2 last year • Negative impact
Slide 13: Adj. FCF in H1 was DKK 1,137 million
Adj. FCF in H1 was DKK 1,137 million. Operating cash flow impacted by increased working capital; NWC-to-sales still expected at 24% for FY FCF development1 FCF development Comments H1 2022/23 highlights • Free cash flow for H1 2022/23 was an inflow of DKK 795 million compared to an outflow of DKK 9,
Slide 14: FY 2022/23 guidance narrowed
FY 2022/23 guidance narrowed – organic growth of around 8% and reported EBIT margin of 28-29%1 GUIDANCE 2022/23 GUIDANCE (DKK)* KEY ASSUMPTIONS • Chronic Care ex. China expected to grow largely in line with Strive25 ambitions: Europe – continued good momentum; US – sustained good momentum in Ostomy
Slide 15: FY 2022/23 guidance breakdown: input cost impact on EBIT margin
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Development since issue of FY guidance Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 Positive Unchanged Negative FY 2022/23 organic growth expected at 68.8 IL
Slide 16: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina | OC user
Slide 17: Coloplast has five business areas with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2021/22 by segment1 Group revenue 2021/22 by geography 1 Continence Care 34% European 1 markets 57% Ostomy Care Other developed 38% markets DKK DKK 26% 22.6bn 22.6bn 1 Voice & Respiratory 4 Care Interventional 5% Urology
Slide 18: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Ostomy Care People who have had their intestine redirected to SenSura® Mio an opening in the abdominal wall Ostomy bag Continence Care People in need of bladder or bowel management SpeediCath® Flex Flex
Slide 19: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 6 7 7 7
Slide 20: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 21: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Voice & Respiratory Interventional Wound Emerging Care Care Care (Laryngectomy) Urology Care Addressable market 20-21bn 15-16bn 1–1.5bn 13-14bn 24-26bn Size in DKK 4
Slide 22: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Channel consol
Slide 23: Our Strive25 strategy will drive long-term value creation
Our Strive25 strategy will drive continued long-term value Continence creation through Care Ostomy Wound and revenue and earnings Care Skin Care growth Interventional Voice and Urology Respiratory Care Innovation Leadership, culture 7-9% more than 30% and organization organic growth EBIT margin1 p.a
Slide 24: Clear path to organic growth in upper end of 7-9% range
Clear path to organic growth in the upper end of the 7-9% range in the outer part of Strive25 7-9% 7-8% Strive25 ambition: Strive25 ambition: Strive25 ambition: Organic growth 10%+ organic growth in Double-digit organic Launch of the Clinical of 8-10% US Chronic Care growth above the Performance mar
Slide 25: Strive25 emphasis on environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions1 and Packaging1 90% of packaging recyc
Slide 26: Incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas We expect to invest up to 2% Economics & Government Innovation of revenue in incremental OPEX investments Chronic Care
Slide 27: Actively pursuing M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: Atos Medical Hope Medical Supply1 TFL Drive Nine Continents Rocky Mountain Medical Suppl
Slide 28: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Superior, clinically Direct Businesses differentiated products Coloplast Consumer Care Consumer preference Data and digital tools Clinical preference Direct to Consumer Data & Digi
Slide 29: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 30: Clinical Performance Programme to tackle users' biggest issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face 45 of users describe UTIs are their %* 2.7 UTIs per user on average every year1 93 % worry about leakage2 greatest challenge in life1 1 Source: Coloplast IC user survey, January 2016 (n=2,942),
Slide 31: Solid progress on Heylo and Luja
Solid progress on Heylo™ and Luja™; Luja is launched in four markets and is expected to be available in key markets over the next 9 months Status May 2023 Expected launch • Product launched in four markets Luja™ Product launch expected new catheter • The results of the first pivotal clinical study h
Slide 32: Leakage remains the biggest challenge for our users
Leakage remains the biggest challenge for our users 91% of people with a stoma worry about leakage1 40 % of users experience leakage onto their clothes every month2 Heylo addresses the mental burden caused by fear of leakage Control and peace of mind 1. Claessenes et. al. Gastrointestinal Nursing 20
Slide 33: Data on Heylo is promising
Data on Heylo™ is promising. Pre-pilot study shows high product performance and user preference Product performance & user experience1 Quality of life and future use1 reduction in worry of leakage 92%* % +9 emotional impact of leakage significant improvement to less leakage episodes 85 %** % 96 secu
Slide 34: Clinical program supports launches and reimbursement applications
The clinical program supports national launches, reimbursement applications and generates user insights Single-arm confirmatory study, n=100 Show benefit to support Drug Tariff application: • Leakage onto clothes • Quality of Life • Healthcare utilisation • Support reimbursement in DE & UK Cross-ove
Slide 35: Preventing UTIs remains one of the biggest unmet needs
Preventing UTIs % remains one of the 45% 48 biggest unmet of users consider of users are UTIs to be their worried whether needs we need to greatest challenge1 they have emptied solve for in IC their bladder4 IC users have 2-3 UTIs on average per year…2 …over a lifetime users will have up to 1 IC Val
Slide 36: Luja with Micro-hole Zone Technology addresses UTI risk factors
Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja™ Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factor
Slide 37: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja™ to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on the key risk factors of UTIs Pilot studies Multicenter, randomised cross 8 studies comparing Luja vs. ove
Slide 38: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, %* Cost item Development, in % of revenue* YTD 22/23 Gross Profit negatively impacted by inflationary headwind on input 1.8%-points costs (raw materials, en
Slide 39: Automation, procurement and scale bring Global Operations to next level
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE # of FTE release through automation, original plan • Due to longer component lead 9% ~600 >1,000 times, the timeline of the DKK ~450m ~500 CAPEX investment ov
Slide 40: Global Business Support and IT landscape enables scaling
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 41: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and R&D costs >30% especially dri
Slide 42: Continued strong free cash flow development during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 6% 5% 4% 5% 4% 4% 4% 4% 26% 24% 23% 24% 25% ~
Slide 43: Attractive cash returns despite investments and Atos acquisition
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical acquisition Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liqui
Slide 44: In sum, stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 28% • Stable market trends in our 12% Chronic Care business 8% • Innovative product portfolio and new product 7% launches 07/08 09/10 11/12 13/14 15/16 17
Slide 45: Introduction to Atos Medical
Introduction to Atos Medical The global market leader in laryngectomy | Atos user
Slide 46: Atos Medical is the global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Key market and business highlights Revenue by segment and geography Laryngectomy Tracheostomy Other ~50,000 New total laryngectomies per year Organic CAGR ~8% ~85% Global Laryngectomy market share
Slide 47: Atos improves lives of patients after Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 48: Untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 49: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 50: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with Synergies
Slide 51: Leading intimate healthcare – Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Tabitha | IC user
Slide 52: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 4.0% 7.0% ~206.9 billion DKK (~30 billion USD) market cap @ ~974.2 DKK per sha
Slide 53: Capital structure
Capital structure Comments Net interest-bearing debt • Overall policy is that excess liquidity is returned to 2.6x shareholders through a combination of dividends and 2.3x share buy-backs 2.0x 21,008 • Bi-annual dividends 18,091 • Share buy-backs of DKK 500m per year 0.3x 1.0x expected – no buy-back
Slide 54: Solid organic growth of 8% in H1 2022/23
Solid organic growth of 8% in H1 2022/23 with solid momentum across business areas and geographies, excluding China H1 2022/23 revenue by business area H1 2022/23 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth Share of
Slide 55: H1 reported growth up 14% with Atos impact
H1 reported growth was up 14%, with ~6%-points impact from the Atos Medical acquisition and limited contribution from currencies H1 2022/23 Revenue development (DKKm) H1 2022/23 highlights • Organic growth was 8% or DKK 804 million, driven by: 1,495m DKK • Solid growth in Chronic Care across regions
Slide 56: Reported EBIT margin of 28% in H1
Reported EBIT margin of 28%1 in H1, reflecting an impact from cost inflation, increased level of commercial activity and amortisation costs H1 2022/23 EBIT margin development before special items (%) H1 2022/23 highlights • Gross margin was 67%, against 69% in H1 last year 31.3 -1.3 • Negative impac
Slide 57: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 32.7 32.8 36.2 36.8 32.3 34.7 34.6 34.7 31.2 32.0 31.5 32.7 28.7 29.0 28.7 28.2 30.1 30.8 25.4 26.2 23.4 23.6 23.4 23.7 4.0 4.2 4.1 3.9 4.5 4.7 5.0 5.2 5.0 4.7 4.1 3.5 3.9 3.9 3.8 3.9 3.8 3.5 17/18 18/19 19/20 20/21 21/22 YTD 22/23 17/18
Slide 58: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care 8 6 6 10 7 19 16 19 7 7 6 13 Contribution to reported growth 6%-points 6%-points 5 4 14 8,620 14 7,841 Organic growth (2 months) 9% 7,166 7,538 10 9 4,478 -7 2,424 1,970 1,835 -7 2,097 NA NA NA
Slide 59: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 4 15 12 2 5 6 6 16 21 22 2 4 12,916 10,573 10,820 11,261 8 6 11 11 6 6,878 3 5 4,785 5,775 4,380 4,644 3,187 18/19 19/20 20/21 21/22 YTD 22/23 18/19 19/20 20/21 21/22 YTD 22/23 FY 21/22 and YTD 22/23 reported growt
Slide 60: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Segment Operating Profit DKKm Segment Operating Profit Margin (%) Chronic Care Interventional Urology Wound & Skin Care Voice & Respiratory Care Ostomy and Continence Care 59 59 58 58 57 2,397 2,500 2,456 2,375 31 35 37 36 35 40 42 2,357
Slide 61: H1 2022/23 Atos Medical impact on EBIT
H1 2022/23 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 33% 3% 30% 29% 28% 0% 28% 1% 0% DKK 33 DKK 107 DKK 60 DKK 362 million million million million EBIT margin Special items EBIT margin Atos EBIT H1 Amortisation EBITA Depreciation EBITDA after special Atos Medical1 H1 2022/23 M
Slide 62: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2022/23 and hedging policy Revenue FX exposure 2022/23(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -490 USD -220 EUR 36% CNY, JPY, AUD, BRL & ARS -320 12% GBP -220 HUF 0 130 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 63: US Mesh litigation – financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets Actual/Expected cash flow, DKKbn 13/14 - 18/19 19/20 20/21 21/22 YTD Restricted cash, DKKbn Actual cash flow Expected cash flow 17/18 22/23 0.5 0.5 EBIT (before s
Slide 64: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC • Italy: Regional payback system (retroactive) 64 Reimbursement pressure
Slide 65: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 66: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience 66
Slide 67: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 67
Slide 68: Interventional Urology revenue balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance 15-20% market share in global market of DKK 13-14bn FY 21/22 market growing 3-5% annually 11% Coloplast position, FY 21/22 of Coloplast sales Endourology Men’s Health Wom
Slide 69: Interventional Urology four business areas and select products
Coloplast Interventional Urology is split into four business areas Men’s Women’s Bladder health Endourology & surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 70: Strong presence in Interventional Urology with room to capture share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 71: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 72: Growth through product and therapy expansion
We will deliver growth through product and therapy expansion Tissue Fixation System Implantable Tibial Nerve TECHNOLOGY ASSESSMENT Stimulator Launched 22/23 Launching 25/26 ACTIVELY PURSUING POP SUI AUS Cancer ED IU Today OAB Endo Endo Consum- ables Laser Endo Visualization Soprano® BPH Hybrid Guide
Slide 73: Nine Continents acquisition enters OAB market with Intibia
With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB symptoms proce
Slide 74: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn Market si
Slide 75: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 76: In US Ostomy Care we continue to win across patient pathway
In US Ostomy Care we continue to win across patient pathway We have gained significant share over the last years … as we work on multiple fronts to win across the patient pathway 3-5 days >60 days ~10 years Bags & Plates acute share Acute Post-acute Community +10%-pts Patients’ first (incl. HHA) Lon
Slide 77: Awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract start date Contract Contract Acute share2 length type 3,6
Slide 78: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 79: H1 22/23 progress on key sustainability ambitions
H1 22/23 progress on key sustainability ambitions Improving products and packaging Reducing emissions2 Responsible operations 2025 H1 FY 2025 H1 FY 2025 H1 FY Ambition 22/23 21/22 Ambition 22/23 21/22 Ambition 22/23 21/22 100% 2.3 2.4 90% 2.0 Recyclable 78% Scope 1+2 emissions Lost time injury packa
Slide 80: Ostomy Care
Introducing Key products Ostomy Care Disease areas • Colorectal cancer (est. 45%) • Bladder cancer (est. 10%) SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • Diverticulitis (est. 15%) Launched in 2018-2019 Launched in 2015 Launched in 2014 • Inflammatory bowel disease (est. 10%) • Other (est
Slide 81: Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape Designed for leakage and skin Reducing skin problems Elastic so it follows • Market size of DKK 3-4bn protection without affecting adhesion the body and • Marke
Slide 82: Continence Care
Introducing Key products Continence Care Disease areas • Spinal Cord Injured, SCI Luja™ SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Spina Bifida, SB Intermittent catheter with Intermittent Set catheter Intermittent catheter Intermittent catheter • Multiple Sclerosis, MS Micro-hole Zone
Slide 83: Bowel Management
Introducing Key products Bowel Management Disease areas Faecal incontinence (management products only) Peristeen® Plus Anal Irrigation Peristeen® Anal Irrigation Launched in 2021 Launched in 2003 Customer groups Updated in 2011 • Spinal Cord Injured, SCI • Spina Bifida, SB • Multiple Sclerosis, MS M
Slide 84: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life ™ Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total Provox® Life ™ laryngectomy, a typical treatment for Adhesive advanced laryngeal
Slide 85: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are Portfolio expansion blocked, or when a disease or other problem • Strengthened the tracheostomy makes normal breathi
Slide 86: Surgical treatment of urological disorders
Introducing Key products Interventional Urology Surgical treatment of urological disorders Disease areas Titan® Touch Inflatable Penile Prosthesis Altis® single incision sling • Urinary incontinence Launched in 2013, Men’s health Launched in 2012 Women’s health – Surgical Urology • Pelvic organ prol
Slide 87: Wound Care
Key products Introducing Wound Care Disease areas Chronic wounds Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact • Leg ulcers Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. • Diabetic foot ulcers border. Launched in 2021 Launched in 2020 Launched in 2
Slide 88: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 89: US Skin Care
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK 4-5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 90: Coloplast organisation structure
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Ostomy Care Continence Care & Skin Care Urology Respiratory Care Marketing Marke
Slide 91: Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 92: Income statement
Income statement DKKm Q2 2021/22 Q2 2022/23 Change H1 2021/22 H1 2022/23 Change Revenue 5,502 6,061 10% 10,671 12,166 14% Gross profit 3,781 4,027 7% 7,311 8,173 12% SG&A costs -1,884 -2,159 15% -3,571 -4,321 21% R&D costs -222 -209 -6% -427 -425 0% Other operating income/expenses 11 12 9% 22 18 -18
Slide 93: Balance sheet
Balance sheet DKKm 31 Mar 2022 31 Mar 2023 Change Balance, total 35,170 35,302 0% Assets Non-current assets 27,001 25,979 -4% Current assets 8,169 9,323 14% of which: Inventories 2,870 3,512 22% Trade receivables 3,648 3,988 9% Marketable securities, cash, and cash equivalents 737 644 -13% 675 Equit
Slide 94: Cash flow
Cash flow DKKm H1 2021/22 H1 2022/23 Change EBIT 2,920 3,412 17% Amortisation 87 167 92% Depreciation 324 362 12% Adjustment for other non-cash operating items 172 -81 nm Change in working capital -1,086 -1,289 19% Net interest payments -52 -143 175% Paid tax -984 -1,252 27% Cash flow from operation
Slide 95: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 3% 5% Hörby Hungary Mørdrup 0% Tatabánya China 11% Minneapolis Nieder-Olm 4% Nyirbátor Mankato Sarlat US/France Denmark Zhuhai Costa Rica Costa Rica Atos (SE/DE) 77% COGS by cost type² 11% 9% Salary - Direct 6% 12% Salary - Indirect Materials (RM &
Slide 96: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,700 T
Slide 97: Production sites
Production sites Denmark Germany Mørdrup Nieder-Olm • Pilot development work Ostomy care, • Specialised production Continence care and Wound care • Research & Development centre and • Adhesives production manufacturing of tracheostomy products • Number of employees in production: ~200 • Number of em
Slide 98: Global Operations Plan 6 themes
Our Global Operations Plan 6 will be announced in 2023, key themes will be resilience and optimizing the footprint Moving focus of GOP6 to further strengthening our model while delivering continued leverage effect on fixed costs and efficiency improvement 2008 2009 2012 2017 2020 2023-2026 Turn-arou
Slide 99: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 100: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Senior Director, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Office: +45 4911 1800 Office: +45 4911 1800 dkadim@coloplast.com dkkhu@
Slide 101: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding